3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
59
INDUSTRY
27
NIH
19
NETWORK
2
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
pembrolizumab
2
apalutamide
2
abiraterone
2
Testosterone
2
Radiosurgery
2
Leuprolide
2
Golytely
2
Exercise
2
Cryotherapy
2
Abiraterone Acetate
2
zanubrutinib
1
venetoclax
1
stenoparib
1
relugolix
1
olaparib
1
nilutamide
1
leucoselect phytosome
1
ibrutinib
1
histrelin
1
enzalutamide
1
copanlisib
1
capivasertib
1
bicalutamide
1
avelumab
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
acalabrutinib
1
Waiting Lists
1
Triptorelin Pamoate
1
Temozolomide
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
FED
×
ibrutinib
×
1 year
×
Clear all
NCT06520098
2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled